Search

Intellia Therapeutics Inc

Gesloten

SectorGezondheidszorg

12.14 -0.74

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.86

Max

12.32

Belangrijke statistieken

By Trading Economics

Inkomsten

-107M

-203M

Verkoop

-7.4M

7.7M

EPS

-0.8

Winstmarge

-2,648.714

Werknemers

377

EBITDA

-11M

-105M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+68.86% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

158M

1.7B

Vorige openingsprijs

12.88

Vorige sluitingsprijs

12.14

Nieuwssentiment

By Acuity

67%

33%

274 / 339 Rangschikking in Healthcare

Intellia Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 sep 2026, 23:11 UTC

Intellia Therapeutics Inc is experiencing a modest decline in after-market hours, trading near the lower end of its one-month range.

17 sep 2026, 20:02 UTC

Correlated Moves

Intellia Therapeutics is advancing sharply, reflecting positive trends in biotechnology, while the ARK Genomic Revolution ETF gains from strong performances by Tempus AI and others.

16 sep 2026, 23:11 UTC

Intellia Therapeutics Inc is trading higher in after-market hours, supported by stronger-than-expected U.S. retail sales data indicating robust consumer spending.

15 sep 2026, 23:02 UTC

Social Media

Intellia Therapeutics Inc shares are higher in after-market hours amid ongoing discussions about its Biologics License Application and market sentiment.

14 sep 2026, 20:07 UTC

Intellia Therapeutics shares are higher, rebounding from earlier session lows amid a broader market recovery, though still below the 20-day moving average.

10 sep 2026, 19:16 UTC

Intellia Therapeutics Inc shares are lower today, following a notable decline from Wednesday's close amid broader market sentiment after the ECB raised interest rates.

8 sep 2026, 20:07 UTC

News
Social Media
Event

Intellia Therapeutics' shares decline despite FDA accepting its lonvo-z application for Priority Review, targeting a decision by March 2027.

3 sep 2026, 19:16 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting sector pressure and a notable decline in first-quarter results. Correlated asset CRISPR Therapeutics also experienced a downturn.

1 sep 2026, 20:09 UTC

Intellia Therapeutics is lower today, tracking broader market declines amid rising oil prices and increased U.S. Treasury yields, which raise inflation concerns.

31 aug 2026, 23:21 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from recent declines and positioned above their 20-day moving average.

28 aug 2026, 20:08 UTC

Intellia Therapeutics shares are lower today, continuing a recent downward trend amid rising U.S. Treasury yields and broader market weakness. No specific news was identified.

27 aug 2026, 23:41 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from an earlier dip and surpassing their 20-day moving average. No specific news was identified.

26 aug 2026, 23:11 UTC

Intellia Therapeutics Inc is higher in after-market hours, reflecting broader market gains. The asset remains above its 20-day moving average and near its one-month range.

25 aug 2026, 20:09 UTC

News
Correlated Moves

Citizens reiterated its Market Outperform rating on Intellia Therapeutics and maintained a $30 price target, contributing to positive sentiment and higher shares.

24 aug 2026, 23:01 UTC

Intellia Therapeutics shares declined after-market, moving lower from Monday's close. The stock remains above its 20-day moving average and near its one-month range.

21 aug 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

20 aug 2026, 19:26 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting declines in the biotechnology sector and the Russell 2000 Index amid challenging market conditions.

19 aug 2026, 20:02 UTC

Correlated Moves

Intellia Therapeutics shares are higher today, reflecting strong investor interest and positive sentiment in the genomics sector, aided by gains in ARK and CRSP.

17 aug 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher, continuing an upward trend since Friday amid positive sentiment in the biotechnology sector and rising long-term Treasury yields.

14 aug 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc. shares rose in after-market trading, reflecting positive market dynamics. The stock remains above its 20-day moving average.

11 aug 2026, 19:33 UTC

News

Intellia Therapeutics shares are lower after Brookline Capital Markets revised Q2 2026 earnings estimates to a loss of -$0.80 per share.

10 aug 2026, 19:46 UTC

News

Intellia Therapeutics shares rise as analysts boost price targets, with Wedbush raising its target to $17.00 while maintaining a “neutral” rating.

7 aug 2026, 19:26 UTC

News
Correlated Moves

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

6 aug 2026, 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

4 aug 2026, 19:36 UTC

Correlated Moves

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

3 aug 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

31 jul 2026, 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30 jul 2026, 17:57 UTC

Correlated Moves
News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29 jul 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28 jul 2026, 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Intellia Therapeutics Inc Prognose

Koersdoel

By TipRanks

68.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.5 USD  68.86%

Hoogste 49 USD

Laagste 9 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Intellia Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

6

Buy

4

Hold

2

Sell

Sentiment

By Acuity

274 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.